Diabetes mellitus, a metabolic disease marked by persistently high blood sugar, is a major global health concern. Side effects, resistance, and the incapacity to adequately address oxidative stress and related consequences are frequently the limitations of current therapeutic approaches. Current treatment approaches are frequently constrained by resistance, side effects, and the incapacity to adequately address oxidative stress and its related consequences. The structural diversity, biocompatibility, and biological pathway modulation of Schiff base metal complexes (SBMs) have made them attractive candidates in the hunt for new antidiabetic drugs. Multiple modes of action are demonstrated by these complexes, such as insulin-mimetic activity, inhibition of important enzymes including α-amylase and α-glucosidase, and antioxidant qualities that reduce oxidative stress. In the context of treating diabetes, recent developments in the synthesis, design, and biological assessment of SBMs have been modelled using ANFIS. Their structure-activity connections, pharmacological potential and clinical translation prospects are highlighted. The results highlight the minimum error values, high correlation coefficient R 2 as 0.90, and function of SBMs as cutting-edge strategies to treat diabetes mellitus’s complicated nature.